NVX‐Cov2373 Novavax Covid‐19 vaccine: A further analysis of its efficacy using multiple modes of expression
A fifth vaccine against Covid‐19, NVX‐CoV2373 Nuvavoxid® (Novavax), a protein‐based adjuvanted vaccine, was recently marketed in Europe. The main clinical trial before marketing concluded to a ‘vaccine efficacy’ of 89.7% without talking about other validated efficacy parameters. We further analysed...
Gespeichert in:
| Veröffentlicht in: | Fundamental & clinical pharmacology 2022-12, Vol.36 (6), p.1125-1127 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1127 |
|---|---|
| container_issue | 6 |
| container_start_page | 1125 |
| container_title | Fundamental & clinical pharmacology |
| container_volume | 36 |
| creator | Montastruc, Jean‐Louis Biron, Pierre Sommet, Agnès |
| description | A fifth vaccine against Covid‐19, NVX‐CoV2373 Nuvavoxid® (Novavax), a protein‐based adjuvanted vaccine, was recently marketed in Europe. The main clinical trial before marketing concluded to a ‘vaccine efficacy’ of 89.7% without talking about other validated efficacy parameters. We further analysed the data of this clinical trial using the different validated methods of risk expression: absolute risks (AR), AR reduction (ARR) and number needed to treat (NNT). ARR and NNT values were 1.22% and 82, respectively, for an RR value of 0.10. Description of these parameters allowed defining some interesting characteristics of NVX‐CoV2373 efficacy according to age, race, variant and coexisting illness. Finally, we ask that the results of clinical trials be systematically presented, using not only RR but also including AR, ARR and NNT. |
| doi_str_mv | 10.1111/fcp.12794 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9348229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2659228099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4434-d4c5317f74b964ea2f17b0fdae7b69ec80630dac1619bbeccb9e37f8e1ef92cf3</originalsourceid><addsrcrecordid>eNp10c1qFTEYBuAgFnusLrwBCbjRxbT5m8nEhVAOVguldaHiLmQyX9qUmck0mRl7dl6C1-iVmPa0RQWzCUkeXj7yIvSCkn2a14Gz4z5lUolHaEWFZEXNSPUYrYisZMFVTXfR05QuCaGS0OoJ2uVlSZgo1QqF06_ffv34uQ4L45Lj07CYxVzjfPZtvqcKL8ZaP8BbfIjdHKcLiNgMptskn3Bw2E8Jg3PeGrvBc_LDOe7nbvJjB7gPLdwiuB4jpOTD8AztONMleH6376EvR-8_rz8WJ2cfjteHJ4UVgouiFbbkVDopGlUJMMxR2RDXGpBNpcDWpOKkNZZWVDUNWNso4NLVQMEpZh3fQ--2uePc9NBaGKZoOj1G35u40cF4_ffL4C_0eVi04qJmTOWA13cBMVzNkCbd-2Sh68wAYU6aVaVirCbqhr76h16GOeY_ykpyUQpeEprVm62yMaQUwT0MQ4m-qVHnGvVtjdm-_HP6B3nfWwYHW_Ddd7D5f5I-Wn_aRv4GLgyqHg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2734543501</pqid></control><display><type>article</type><title>NVX‐Cov2373 Novavax Covid‐19 vaccine: A further analysis of its efficacy using multiple modes of expression</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Montastruc, Jean‐Louis ; Biron, Pierre ; Sommet, Agnès</creator><creatorcontrib>Montastruc, Jean‐Louis ; Biron, Pierre ; Sommet, Agnès</creatorcontrib><description>A fifth vaccine against Covid‐19, NVX‐CoV2373 Nuvavoxid® (Novavax), a protein‐based adjuvanted vaccine, was recently marketed in Europe. The main clinical trial before marketing concluded to a ‘vaccine efficacy’ of 89.7% without talking about other validated efficacy parameters. We further analysed the data of this clinical trial using the different validated methods of risk expression: absolute risks (AR), AR reduction (ARR) and number needed to treat (NNT). ARR and NNT values were 1.22% and 82, respectively, for an RR value of 0.10. Description of these parameters allowed defining some interesting characteristics of NVX‐CoV2373 efficacy according to age, race, variant and coexisting illness. Finally, we ask that the results of clinical trials be systematically presented, using not only RR but also including AR, ARR and NNT.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/fcp.12794</identifier><identifier>PMID: 35502459</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>absolute risk reduction ; Clinical trials ; COVID-19 ; Covid‐19 vaccines ; Effectiveness ; number needed to treat ; NVX‐Cov2373 Covid‐19 vaccine ; Parameters ; Pharmacology ; relative risk ; Short Communication ; Short Communications ; Vaccine efficacy ; Vaccines</subject><ispartof>Fundamental & clinical pharmacology, 2022-12, Vol.36 (6), p.1125-1127</ispartof><rights>2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.</rights><rights>2022 John Wiley & Sons, Ltd.</rights><rights>2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4434-d4c5317f74b964ea2f17b0fdae7b69ec80630dac1619bbeccb9e37f8e1ef92cf3</citedby><cites>FETCH-LOGICAL-c4434-d4c5317f74b964ea2f17b0fdae7b69ec80630dac1619bbeccb9e37f8e1ef92cf3</cites><orcidid>0000-0001-6341-6001</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ffcp.12794$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ffcp.12794$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,777,781,882,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35502459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montastruc, Jean‐Louis</creatorcontrib><creatorcontrib>Biron, Pierre</creatorcontrib><creatorcontrib>Sommet, Agnès</creatorcontrib><title>NVX‐Cov2373 Novavax Covid‐19 vaccine: A further analysis of its efficacy using multiple modes of expression</title><title>Fundamental & clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>A fifth vaccine against Covid‐19, NVX‐CoV2373 Nuvavoxid® (Novavax), a protein‐based adjuvanted vaccine, was recently marketed in Europe. The main clinical trial before marketing concluded to a ‘vaccine efficacy’ of 89.7% without talking about other validated efficacy parameters. We further analysed the data of this clinical trial using the different validated methods of risk expression: absolute risks (AR), AR reduction (ARR) and number needed to treat (NNT). ARR and NNT values were 1.22% and 82, respectively, for an RR value of 0.10. Description of these parameters allowed defining some interesting characteristics of NVX‐CoV2373 efficacy according to age, race, variant and coexisting illness. Finally, we ask that the results of clinical trials be systematically presented, using not only RR but also including AR, ARR and NNT.</description><subject>absolute risk reduction</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>Covid‐19 vaccines</subject><subject>Effectiveness</subject><subject>number needed to treat</subject><subject>NVX‐Cov2373 Covid‐19 vaccine</subject><subject>Parameters</subject><subject>Pharmacology</subject><subject>relative risk</subject><subject>Short Communication</subject><subject>Short Communications</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp10c1qFTEYBuAgFnusLrwBCbjRxbT5m8nEhVAOVguldaHiLmQyX9qUmck0mRl7dl6C1-iVmPa0RQWzCUkeXj7yIvSCkn2a14Gz4z5lUolHaEWFZEXNSPUYrYisZMFVTXfR05QuCaGS0OoJ2uVlSZgo1QqF06_ffv34uQ4L45Lj07CYxVzjfPZtvqcKL8ZaP8BbfIjdHKcLiNgMptskn3Bw2E8Jg3PeGrvBc_LDOe7nbvJjB7gPLdwiuB4jpOTD8AztONMleH6376EvR-8_rz8WJ2cfjteHJ4UVgouiFbbkVDopGlUJMMxR2RDXGpBNpcDWpOKkNZZWVDUNWNso4NLVQMEpZh3fQ--2uePc9NBaGKZoOj1G35u40cF4_ffL4C_0eVi04qJmTOWA13cBMVzNkCbd-2Sh68wAYU6aVaVirCbqhr76h16GOeY_ykpyUQpeEprVm62yMaQUwT0MQ4m-qVHnGvVtjdm-_HP6B3nfWwYHW_Ddd7D5f5I-Wn_aRv4GLgyqHg</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Montastruc, Jean‐Louis</creator><creator>Biron, Pierre</creator><creator>Sommet, Agnès</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6341-6001</orcidid></search><sort><creationdate>202212</creationdate><title>NVX‐Cov2373 Novavax Covid‐19 vaccine: A further analysis of its efficacy using multiple modes of expression</title><author>Montastruc, Jean‐Louis ; Biron, Pierre ; Sommet, Agnès</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4434-d4c5317f74b964ea2f17b0fdae7b69ec80630dac1619bbeccb9e37f8e1ef92cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>absolute risk reduction</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>Covid‐19 vaccines</topic><topic>Effectiveness</topic><topic>number needed to treat</topic><topic>NVX‐Cov2373 Covid‐19 vaccine</topic><topic>Parameters</topic><topic>Pharmacology</topic><topic>relative risk</topic><topic>Short Communication</topic><topic>Short Communications</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Montastruc, Jean‐Louis</creatorcontrib><creatorcontrib>Biron, Pierre</creatorcontrib><creatorcontrib>Sommet, Agnès</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Fundamental & clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montastruc, Jean‐Louis</au><au>Biron, Pierre</au><au>Sommet, Agnès</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NVX‐Cov2373 Novavax Covid‐19 vaccine: A further analysis of its efficacy using multiple modes of expression</atitle><jtitle>Fundamental & clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2022-12</date><risdate>2022</risdate><volume>36</volume><issue>6</issue><spage>1125</spage><epage>1127</epage><pages>1125-1127</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><abstract>A fifth vaccine against Covid‐19, NVX‐CoV2373 Nuvavoxid® (Novavax), a protein‐based adjuvanted vaccine, was recently marketed in Europe. The main clinical trial before marketing concluded to a ‘vaccine efficacy’ of 89.7% without talking about other validated efficacy parameters. We further analysed the data of this clinical trial using the different validated methods of risk expression: absolute risks (AR), AR reduction (ARR) and number needed to treat (NNT). ARR and NNT values were 1.22% and 82, respectively, for an RR value of 0.10. Description of these parameters allowed defining some interesting characteristics of NVX‐CoV2373 efficacy according to age, race, variant and coexisting illness. Finally, we ask that the results of clinical trials be systematically presented, using not only RR but also including AR, ARR and NNT.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35502459</pmid><doi>10.1111/fcp.12794</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-6341-6001</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0767-3981 |
| ispartof | Fundamental & clinical pharmacology, 2022-12, Vol.36 (6), p.1125-1127 |
| issn | 0767-3981 1472-8206 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9348229 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | absolute risk reduction Clinical trials COVID-19 Covid‐19 vaccines Effectiveness number needed to treat NVX‐Cov2373 Covid‐19 vaccine Parameters Pharmacology relative risk Short Communication Short Communications Vaccine efficacy Vaccines |
| title | NVX‐Cov2373 Novavax Covid‐19 vaccine: A further analysis of its efficacy using multiple modes of expression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A36%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NVX%E2%80%90Cov2373%20Novavax%20Covid%E2%80%9019%20vaccine:%20A%20further%20analysis%20of%20its%20efficacy%20using%20multiple%20modes%20of%20expression&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Montastruc,%20Jean%E2%80%90Louis&rft.date=2022-12&rft.volume=36&rft.issue=6&rft.spage=1125&rft.epage=1127&rft.pages=1125-1127&rft.issn=0767-3981&rft.eissn=1472-8206&rft_id=info:doi/10.1111/fcp.12794&rft_dat=%3Cproquest_pubme%3E2659228099%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2734543501&rft_id=info:pmid/35502459&rfr_iscdi=true |